Skip to main content
eScholarship
Open Access Publications from the University of California

Glucocorticoids reduce bone strength through reduction in vascularity and hydration, while concurrent treatment with PTH increases bone mass and preserves angiogenic and nitric oxide gene expression in glucocorticoid-treated mice

The data associated with this publication are not available for this reason: N/A
Abstract

Glucocorticoids (GC) induce osteonecrosis (ON) and osteoporosis (OP); however, themechanism is complicated. While GCs may increase the risk of ON by reducing angiogenesis and vasoactivity, the reduction in bone strength that accompanies GC use is greater than can be explained by the loss of bone mass alone. To try to understand this discrepancy, we evaluated GC’s effects on novel bone quality measures, including bone bone hydration, bone blood flow, and bone angiogenesis gene expression. We performed two experiments. The first was to understand the role of GC on bone hydration, bone blood flow, and strength, and whether this is altered by anti-vascular endothelial growth factor (VEGF). In the second study we evaluated GC effects on bone vascularity by evaluating gene expression in bone, and if PTH, a known vasculoactive agent, influences this.

Main Content
For improved accessibility of PDF content, download the file to your device.
Current View